Tevogen Inc. TVGNW
Set alert
As of Oct 30, 3:57 PM ET
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.045
- Prev close
- 0.074
- Mkt cap
- 15.35M
- Vol
- 627.93K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0751
- High
- 0.0916
- Forward P/E
- 0.00
- Beta
- -1.03
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- -1.03
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 10.55M
- Total cash
- 1.14M
- Total debt
- 2.02M
- Return on equity
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About Tevogen Inc.
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tevogen.com
News
Your note
Sign in to keep a note on TVGNW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Parallax Volatility Advisers, L.P. | 12.54% | 2,163,677 | 126.36K | Sep 29, 2024 |
| Highbridge Capital Management, LLC. | 11.98% | 2,067,178 | 120.72K | Sep 29, 2024 |
| FourWorld Capital Management, LLC | 8.41% | 1,450,000 | 84.68K | Sep 29, 2024 |
| Corbin Capital Partners, LP | 6.72% | 1,160,000 | 67.74K | Sep 29, 2024 |
| Calamos Advisors LLC | 5.80% | 1,000,000 | 58.40K | Sep 29, 2024 |
| Polar Asset Management Partners Inc. | 4.16% | 717,307 | 41.89K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Merger Fund, The | 0.49% | 83,731 | 4.89K | Sep 29, 2024 |
| WCM Alternatives Event Driven Fund | 0.04% | 6,900 | 402 | Sep 29, 2024 |
| JNL Series Trust-JNL/Multi Manager Alternative Fund | 0.02% | 3,940 | 230 | Sep 29, 2024 |
| Merger Fund Vl, The | 0.01% | 1,068 | 62 | Sep 29, 2024 |
| JNL Series Trust-JNL/Westchester Capital Event Driven Fund | 0.01% | 2,539 | 148 | Sep 29, 2024 |
| Principal Global Multi Strategy Fd | 0.00% | 597 | 34 | Aug 30, 2024 |